January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

January 15, 2025

Cutaneous Head and Neck Melanoma: Better Outcomes with ICIs

Explore the distinct clinicopathological features and treatment outcomes of cutaneous head and neck melanoma versus other melanoma sites.

Conexiant

January 15, 2025

Gender and Site-Specific Trends in Melanoma Incidence

Global analysis reveals distinct melanoma patterns by gender and site, with females showing excess lower limb cases.

Conexiant

January 13, 2025

Melanoma Toolkit Enhances Primary Care Diagnostic Accuracy

"PCPs may serve as a valuable aid in skin cancer screening efforts."

Conexiant

January 09, 2025

Novel Tool for Predicting Response to Immunotherapy in Melanoma Under Study

An international team of scientists from the United Kingdom and the United States has discovered that the activity of macrophages may prove to be useful in predicting whether or not a patient with mel...

The ASCO Post

December 23, 2024

Cancer Drug Side Effect Causes Skin Changes

New research reveals that one-third of cancer patients developed red, inflammatory skin lesions before experiencing vitiligo-like depigmentation from immune checkpoint inhibitor therapy, potentially offering clinicians an early warning sign.

Conexiant

January 05, 2024

Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer

Researchers investigated the potential of a rare subset of T cells to predict which patients with advanced skin cancer may be responsive to immunotherapy.

The ASCO Post

April 30, 2024

Study Explores Impact of Cannabis Extract on Melanoma Cells

The cannabis extract cannabinoid PHEC-66 may effectively treat melanoma.

Conexiant

April 30, 2024

Model for Predicting Survival Following SLNB in Melanoma

Researchers have developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma.

Conexiant